Journal of International Oncology ›› 2017, Vol. 44 ›› Issue (1): 53-56.doi: 10.3760/cma.j.issn.1673-422X.2017.01.014

Previous Articles     Next Articles

Driver genes and targeted drugs in lung cancer

Huang Yan, Yang Jiyuan   

  1. Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou 434000, China
  • Online:2017-01-08 Published:2016-12-07
  • Contact: Yang Jiyuan, Email: yangjiyuanchina@163.com E-mail:yangjiyuanchina@163.com

Abstract: With the development of molecular biology of cancer, molecular targeted therapy which targeted the driver genes in lung cancer has become an inevitable part of the treatment of advanced lung cancer. The most successful examples of targeted therapy are targeting epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). More and more driver genes have been discovered, including ROS1 gene fusion, fibroblast growth factor receptor 1 amplification, KRAS, BRAF, PIK3CA gene mutation and so on. It is meaningful for guiding the treatment of lung cancer that defines the mutation incidence and clinical significance of driver genes in lung cancer.

Key words: Lung neoplasms, Driver genes, Targeted therapy